Information Library

Results for: High-quality studies - Phase I/IIa

To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • The Contribution of Early-phase Clinical Data to a Drug’s Integrated Cardiac Safety Portfolio

    Hear from the Experts — January 16, 2012
    This article examines the financial and time benefits to incorporating intensive ECG and QT/QTc monitoring in early-phase clinical studies.

  • Intarcia and Quintiles Finalize Innovative Alliance

    Press Release — December 13, 2011 – To speed development of a potential ground-breaking therapy for Type 2 diabetes – Intarcia Therapeutics, Inc., and Quintiles announced the signing of definitive agreements making Quintiles a financial and strategic partner for the global clinical development of Intarcia’s ITCA 650 (DUROS® continuous subcutaneous delivery of exenatide).

  • Quintiles Launches China CRO, Kun Tuo

    Press Release — December 13, 2011 – Further deepening its commitment to China, Quintiles announced the launch of Kun Tuo, a local contract research organization (CRO) built to service the unique needs of the Chinese biopharmaceutical industry and multinational biopharma companies operating in China.

  • The Contribution of Early-phase Clinical Data to a Drug’s Integrated Cardiac Safety Portfolio

    Hear from the Experts — December 6, 2011
    This article examines the financial and time benefits to incorporating intensive ECG and QT/QTc monitoring in early-phase clinical studies.

  • Partnering is Key to Maximizing Rewards in Emerging Markets

    Press Release — September 27, 2011 – While biopharmaceutical spending in emerging markets is growing at double-digit rates – much faster than in developed nations – opportunities in “pharmerging” countries must be balanced with accompanying costs and risks of entering new markets.

  • Shifting Sands

    Media Coverage — September 2, 2011
    As the pressure to improve the productivity of clinical development programmes mounts on pharmaceutical companies, the current landscape for locating cost-effective clinical trials continues to evolve. One region attracting attention is the Middle East and North Africa.

  • Quintiles Appoints Global Head of Phase I Division

    Press Release — August 31, 2011 – Quintiles announced that Oren Cohen, M.D., will serve as Senior Vice President and Global Head of its Phase I Clinical Research division, which includes world-class facilities in Overland Park, Kansas (U.S.), London (U.K.) and Hyderabad (India).

  • A Focus on CNS

    Brochure — July 1, 2011
    Quintiles is your ally for broad and deep CNS expertise in every aspect of the drug development process.

  • The Molecular Biomarker Revolution in Non-Small Cell Lung Cancer

    White Paper — June 23, 2011
    In this new white paper Quintiles’ experts Christopher Ung, Jason Hill, Carrie Lee and Harish Dave review some of the most promising molecular pathways and targeted approaches for NSCLC, the critical role of diagnostics, and strategies to detect and address the emergence of resistance.

  • CardioCheck

    White Paper — May 10, 2011
    Quintiles' CardioCheck program is designed to provide rapid insight into potential cardiotoxic influences of pharmaceutical compounds.

Page 1 of 3 (28 results)

Subscribe to Email Based on Your Interests

Set preferences